在药代动力学模型中大肠埃希菌暴露于抗生素-外排泵抑制剂组合:对细菌清除和耐药性的影响
本研究在体外药代动力学模型中观察大肠埃希菌MG1655及其MarR突变株I1147暴露于环丙沙星联合氯丙嗪、PAβN或MBX-4191后的药效学。结果显示氯丙嗪和PAβN的AUC为药效驱动因素,MBX-4191的T>阈值为驱动因素;联合未改变种群谱,但恢复株出现gyrA、gyrB或marR突变。
要点
- 氯丙嗪60 mg/L、PAβN 30 mg/L和MBX-4191 0.5-1.0 mg/L降低I1147的环丙沙星MIC并增强杀菌。
- 氯丙嗪和PAβN以AUC为药效驱动因素,MBX-4191以T>阈值为驱动因素。
- 环丙沙星联合外排泵抑制剂未改变种群谱,但恢复株检出gyrA、gyrB或marR突变。
核心结论
- 氯丙嗪和PAβN的药效驱动因素为AUC,MBX-4191的驱动因素为T>阈值,T>阈值对氯丙嗪和PAβN的活性也重要。
- 环丙沙星联合外排泵抑制剂未出现种群谱变化,但检出gyrA、gyrB和marR突变。
研究设计与样本
- 体外药代动力学模型研究,使用大肠埃希菌MG1655及其同源MarR突变株I1147。
- 测定环丙沙星单用及联合氯丙嗪、PAβN或MBX-4191的MIC,先进行暴露范围实验再进行分数化实验。
- 评估细菌载量和种群谱变化,并对EPI模拟后恢复的菌株进行全基因组测序(WGS)。
主要发现
- 大肠埃希菌MG1655和I1147的环丙沙星MIC分别为0.08和0.03 mg/L。
- 氯丙嗪60 mg/L、PAβN 30 mg/L和MBX-4191 0.5-1.0 mg/L降低I1147的环丙沙星MIC并增强杀菌。
- 环丙沙星AUC为1.2 mg·h/L时,氯丙嗪AUC与24 h细菌载量降低最相关,T>25 mg/L时也与效应强相关。
- 环丙沙星AUC为0.6 mg·h/L时,PAβN AUC与细菌载量降低最相关。
- MBX-4191的T>0.5-0.75 mg·h/L与细菌载量降低最相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efflux pump inhibitors (EPIs) offer an attractive therapeutic option when combined with existing classes. However, their optimal dosing strategies are unknown. METHODS: MICs of ciprofloxacin (CIP)+/-chlorpromazine, phenylalanine-arginine β naphthylamide (PAβN) and a developmental molecule MBX-4191 were determined and the pharmacodynamics (PD) was studied in an in vitro model employing Escherichia coli MG1655 and its isogenic MarR mutant (I1147). Exposure ranging experiments were performed initially then fractionation. Changes in bacterial load and population profiles were assessed. Strains recovered after EPI simulations were studied by WGS. RESULTS: The CIPMICs for E. coli MG1655 and I1147 were 0.08 and 0.03 mg/L. Chlorpromazine at a concentration of 60 mg/L, PAβN concentrations of 30 mg/L and MBX-4191 concentrations of 0.5-1.0 mg/L reduced CIP MICs for I1147 and enhanced bacterial killing. Using CIP at an AUC of 1.2 mg·h/L, chlorpromazine AUC was best related to reduction in bacterial load at 24 h, however, when the time drug concentration was greater than 25 mg/L (T > 25 mg/L) chlorpromazine was also strongly related to the effect. For PaβN with CIP AUC, 0.6 mg·h/L PaβN AUC was best related to a reduction in bacterial load. MBX-4191T > 0.5-0.75 mg·h/L was best related to reduction in bacterial load. Changes in population profiles were not seen in experiments of ciprofloxacin + EPIs. WGS of recovered strains from simulations with all three EPIs showed mutations in gyrA, gyrB or marR. CONCLUSIONS: AUC was the pharmacodynamic driver for chlorpromazine and PAβN while T > threshold was the driver for MBX-4191 and important in the activity of chlorpromazine and PAβN. Changes in population profiles did not occur with combinations of ciprofloxacin + EPIs, however, mutations in gyrA, gyrB and marR were detected.
引用
- MacGowan AP, Attwood MLG, Noel AR, et al. Exposure of Escherichia coli to antibiotic-efflux pump inhibitor combinations in a pharmacokinetic model: impact on bacterial clearance and drug resistance. J Antimicrob Chemother. 2023. PMID: 37837411. doi:10.1093/jac/dkad320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。